Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014115 | Toxemia NIH | 0.45 |
| D018805 | Sepsis NIH | 0.35 |
| D011014 | Pneumonia NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100806 | Sepsis HPO | 0.35 |
| HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There is one clinical trial.
A phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled, dose- finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.
Description: Number and severity of AEs and SAEs throughout 28 days follow up period
Measure: To compare the safety of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Change from baseline in SOFA score throughout 28 days
Measure: To compare the efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Vasopressor-free days over 28 days.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Ventilator-free days over 28 days
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients. Time: 28 daysDescription: Days without renal replacement therapy (dialysis).
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Time in ICU and time in hospital
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number of days with creatinine ≤ Baseline levels +20%.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: All-cause mortality at Day 28 following first dose
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Changes in CRP levels
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number and severity of AEs and Serious Adverse Events (SAEs) throughout 12 months follow up period
Measure: Assess long term safety follow up Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports